PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Determine the Bioequivalence of Two Doses of Tafamidis
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04575116
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1648
- Registration Number
- NCT04574362
- Locations
- π¨π³
1st Hospital of Jilin University, Changchun, Jilin, China
π¨π³Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China
π°π·Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of
Randomized Trial in Adult Participants With Acute Migraines
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1978
- Registration Number
- NCT04571060
- Locations
- πΊπΈ
Meridian Clinical Research, LLC, Savannah, Georgia, United States
πΊπΈPharmQuest LLC, Greensboro, North Carolina, United States
πΊπΈHeadache Wellness Center, Greensboro, North Carolina, United States
Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04564755
- Locations
- πΊπΈ
Beach Allergy and Asthma Specialty Group, A Medical Corporation, Long Beach, California, United States
πΊπΈCahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
πΊπΈAntelope Valley Clinical Trials, Lancaster, California, United States
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Conditions
- LiposarcomaAdenocarcinoma of LungProstate CancerBreast Neoplasms
- Interventions
- Combination Product: LetrozoleCombination Product: EnzalutamideCombination Product: Fulvestrant
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 337
- Registration Number
- NCT04557449
- Locations
- πΈπ°
Narodny onkologicky ustav, Bratislava, Slovakia
πΈπ°Fakultna nemocnica s poliklinikou Nove Zamky, Nove Zamky, Slovakia
πΈπ°POKO Poprad, s.r.o., Poprad, Slovakia
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT04556734
- Locations
- πΊπΈ
UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
πΊπΈUPMC Eye Center, Pittsburgh, Pennsylvania, United States
πΊπΈInvestigate MD, Scottsdale, Arizona, United States
Axitinib Therapy Management Study
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04555603
- Locations
- πΊπΈ
Pfizer Inc., New York, New York, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT04552470
- Locations
- π―π΅
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan
PF-07104091 as a Single Agent and in Combination Therapy
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian Cancer
- Interventions
- Drug: PF-07104091 monotherapy dose escalationDrug: PF-0704091 + Fulvestrant (post CDK4/6)Drug: PF-07104091 + palbociclib + fulvestrantDrug: PF-07104091 + palbociclib + letrozoleDrug: PF-07104091 monotherapy dose expansion (SCLC)Drug: PF-07104091 monotherapy dose expansion (ovarian)Drug: PF-07104091 + Fulvestrant (post CDK4/6)
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT04553133
- Locations
- πΊπΈ
Norton Women's and Children's Hospital (St. Matthews), Louisville, Kentucky, United States
πΊπΈMemorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center (IDS Pharmacy), Long Island City, New York, United States
Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04549480
- Locations
- π³π±
PRA Health Sciences Utrecht, Utrecht, Netherlands
π³π±PRA Health Sciences, Groningen, Netherlands